Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion.
We reported recently that inhibition of neuronal reuptake of norepinephrine (NE) by desipramine prevented the reduction of sympathetic neurotransmitters in the failing right ventricle of right heart failure animals. In this study, we studied whether desipramine also reduced the sympathetic neurotransmitter loss in animals with left heart failure induced by rapid ventricular pacing (225 beats/min) or after chronic NE infusion (0.5 microg. kg(-1). min(-1)). Desipramine was given to the animals for 8 wk beginning with rapid ventricular pacing or NE infusion. Animals receiving no desipramine were studied as controls. We measured myocardial NE content, NE uptake activity, and sympathetic NE, tyrosine hydroxylase, and neuropeptide Y profiles by histofluorescence and immunocytochemical techniques. Effects of desipramine on NE uptake inhibition were evidenced by potentiation of the pressor response to exogenous NE and reduction of myocardial NE uptake activity. Desipramine treatment had no effect in sham or saline control animals but attenuated the reduction of sympathetic neurotransmitter profiles in the left ventricles of animals with rapid cardiac pacing and NE infusion. In contrast, the panneuronal marker protein gene product 9.5 profile was not affected by either rapid pacing or NE infusion, nor was it changed by desipramine treatment in the heart failure animals. The study confirms that excess NE contributes to the reduction of cardiac sympathetic neurotransmitters in heart failure. In addition, it shows that the anatomic integrity of the sympathetic nerves is relatively intact and that the neuronal damaging effect of NE involves the uptake of NE or its metabolites into the sympathetic nerves.
Liang
Chang-seng
CS
Cardiology Unit, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. Chang-seng_Liang@urmc.rochester.edu
Yatani
Akito
A
Himura
Yoshihiro
Y
Kashiki
Michihiro
M
Stevens
Susanne Y
SY
D000320:Adrenergic Fibers / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology*; D000316:Adrenergic alpha-Agonists / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003891:Desipramine / Q000494:pharmacology*; D004285:Dogs; D006321:Heart / Q000294:innervation*; D006333:Heart Failure / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D007150:Immunohistochemistry; D008856:Microscopy, Fluorescence / Q000379:methods; D009478:Neuropeptide Y / Q000378:metabolism; D009638:Norepinephrine / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics*; D013869:Thiolester Hydrolases / Q000032:analysis; D043222:Ubiquitin Thiolesterase
D018759:Adrenergic Uptake Inhibitors; D000316:Adrenergic alpha-Agonists; D009478:Neuropeptide Y; D013869:Thiolester Hydrolases; D043222:Ubiquitin Thiolesterase; D003891:Desipramine; D009638:Norepinephrine